open access

Vol 4, No 6 (2008)
Case report
Published online: 2008-12-16
Get Citation

Reduced doses of rasburicase in prevention of acute tumor lysis syndrome in patient with diffuse large B-cell lyphoma - a case report

Patrycja Binkowska, Jan Maciej Zaucha
Onkol. Prak. Klin 2008;4(6):228-231.

open access

Vol 4, No 6 (2008)
CASE REPORTS
Published online: 2008-12-16

Abstract

Acute tumor lysis syndrome (ATLS) is a group of metabolic complications that can occur as a result of acute lysis of malignant cells after initiation of cytostatic treatment or spontaneously even before introducing chemotherapy. Usually it is observed in patients with hematologic malignancies or solid tumors with high proliferative index. Since ATLS might be life-threatening, it is necessary to identify risk factors of this complication and to introduce prompt prophylactic treatment. Previously, it consisted of hydration, allopurinol administration and urine alcalinization. At present the new possibility of intervention gives us rasburicase - a recombinant urate oxidase, which directly decreases uric acid level catalyzing its conversion to a soluble, easily excreteable metabolite allantoin. High costs of rasburicase treatment at doses recommended by the manufacturer (0.2 mg/kg for 5 days), may discourage from its everyday usage. Here we present the effective administration of lower doses of rasburicase in combination with allopurinol to prevent development of clinical tumor lysis syndrome (CTLS) in a patient with diffuse large B-cell lymphoma. Administration of a single dose of rasburicase (4.5 mg) reduced plasma uric acid level from 14.3 to 0.4 mg/dl which continued to be low during subsequent CHOP chemotherapy. Such a management allowed us to achieve anticipated clinical effect with costs reduction of 96%.

Abstract

Acute tumor lysis syndrome (ATLS) is a group of metabolic complications that can occur as a result of acute lysis of malignant cells after initiation of cytostatic treatment or spontaneously even before introducing chemotherapy. Usually it is observed in patients with hematologic malignancies or solid tumors with high proliferative index. Since ATLS might be life-threatening, it is necessary to identify risk factors of this complication and to introduce prompt prophylactic treatment. Previously, it consisted of hydration, allopurinol administration and urine alcalinization. At present the new possibility of intervention gives us rasburicase - a recombinant urate oxidase, which directly decreases uric acid level catalyzing its conversion to a soluble, easily excreteable metabolite allantoin. High costs of rasburicase treatment at doses recommended by the manufacturer (0.2 mg/kg for 5 days), may discourage from its everyday usage. Here we present the effective administration of lower doses of rasburicase in combination with allopurinol to prevent development of clinical tumor lysis syndrome (CTLS) in a patient with diffuse large B-cell lymphoma. Administration of a single dose of rasburicase (4.5 mg) reduced plasma uric acid level from 14.3 to 0.4 mg/dl which continued to be low during subsequent CHOP chemotherapy. Such a management allowed us to achieve anticipated clinical effect with costs reduction of 96%.
Get Citation

Keywords

tumor lysis syndrome; hyperuricemia; reduced doses of rasburicase

About this article
Title

Reduced doses of rasburicase in prevention of acute tumor lysis syndrome in patient with diffuse large B-cell lyphoma - a case report

Journal

Oncology in Clinical Practice

Issue

Vol 4, No 6 (2008)

Article type

Case report

Pages

228-231

Published online

2008-12-16

Bibliographic record

Onkol. Prak. Klin 2008;4(6):228-231.

Keywords

tumor lysis syndrome
hyperuricemia
reduced doses of rasburicase

Authors

Patrycja Binkowska
Jan Maciej Zaucha

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl